Diamyd Medical AB (OSTO:DMYD B) 3-Year Book Growth Rate : 24.50% (As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB 3-Year Book Growth Rate?

Diamyd Medical AB's Book Value per Share for the quarter that ended in Feb. 2024 was kr1.91.

During the past 12 months, Diamyd Medical AB's average Book Value per Share Growth Rate was -6.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was 24.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was 29.90% per year. During the past 10 years, the average Book Value per Share Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Diamyd Medical AB was 51.30% per year. The lowest was -46.30% per year. And the median was -12.00% per year.

Competitive Comparison of Diamyd Medical AB's 3-Year Book Growth Rate

For the Biotechnology subindustry, Diamyd Medical AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's 3-Year Book Growth Rate falls into.

Diamyd Medical AB 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Diamyd Medical AB (OSTO:DMYD B) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Diamyd Medical AB 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB (OSTO:DMYD B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

DMN:Germany

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB (OSTO:DMYD B) Headlines

No Headlines